# Aleniglipron PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/aleniglipron

> The next catalyst for aleniglipron, sponsored by Structure Therapeutics Inc. (GPCR), is its topline data readout, 2H 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for aleniglipron?

The next catalyst for aleniglipron, sponsored by Structure Therapeutics Inc. (GPCR), is its topline data readout, 2H 2028. Press release filed with the SEC (EX-99): "topline data expected in 2H 2028" [Calendar and source filings](https://sec-api.dev/pdufa/aleniglipron)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-124494, https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/pdufa/aleniglipron#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | aleniglipron |
| Codes | GSBR-1290 |
| Sponsor | Structure Therapeutics Inc. (GPCR) https://sec-api.dev/companies/gpcr/catalysts |
| Indications | people living with obesity and/or overweight, obesity or overweight and type 2 diabetes mellitus |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jan 2023: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2024-11-13, last confirmed 2024-11-13.
- SEC Form 10-Q (accession 0001558370-24-015531): "Furthermore, we initiated the Phase 1b MAD study in January 2023 and completed dosing in otherwise healthy overweight subjects in March 2023." https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm

### May 2023: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2024-11-13, last confirmed 2026-02-26.
- SEC Form 10-K (accession 0001104659-26-020562): "In May 2023, we submitted a protocol amendment to the FDA and initiated dosing of the Phase 2a proof-of-concept study in T2DM and obesity." https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/gpcr-20251231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001826): "In May 2023, we submitted a protocol amendment to the FDA and initiated dosing of the Phase 2a proof-of-concept study in T2DM and obesity." https://www.sec.gov/Archives/edgar/data/1888886/000155837025001826/gpcr-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015531): "In May 2023, we submitted a protocol amendment to the FDA and initiated dosing of the Phase 2a proof-of-concept study in T2DM and obesity." https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm

### Jun 2024: topline data readout

- Status: completed, met. Date confidence: month. Stage: 2.
- First seen 2024-11-13, last confirmed 2026-02-26.
- SEC Form 10-K (accession 0001104659-26-020562): "In June 2024, we reported positive topline data from our Phase 2a obesity study, in which aleniglipron demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks (p<0.0001, using least-squares means ("LSM") and analyzed based on the primary efficacy estimand using a mixed model for repeated measures) and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120 mg." https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/gpcr-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-020562): "In June 2024, the Company reported positive topline data from the Phase 2a obesity study in which GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks (p<0.0001) and generally favorable safety and tolerability results following repeated, daily dosing up to 120 mg." https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/gpcr-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-107829): "In June 2024, we reported positive topline data from our Phase 2a obesity study, in which aleniglipron demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks (p<0.0001, using least-squares means ("LSM") and analyzed based on the primary efficacy estimand using a mixed model for repeated measures) and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120 mg." https://www.sec.gov/Archives/edgar/data/1888886/000110465925107829/gpcr-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010541): "In June 2024, we reported positive topline data from our Phase 2a obesity study, in which aleniglipron demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks (p<0.0001, using least-squares means ("LSM") and analyzed based on the primary efficacy estimand using a mixed model for repeated measures) and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120 mg." https://www.sec.gov/Archives/edgar/data/1888886/000155837025010541/gpcr-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006989): "In June 2024, we reported positive topline data from our Phase 2a obesity study, in which aleniglipron demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks (p<0.0001, using least-squares means ("LSM") and analyzed based on the primary efficacy estimand using a mixed model for repeated measures) and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120mg." https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006989): "In June 2024, we reported positive topline data from our Phase 2a obesity study, in which aleniglipron demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks (p<0.0001, using least-squares means ("LSM") and analyzed based on the primary efficacy estimand using a mixed model for repeated measures) and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120 mg." https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001826): "In June 2024, we reported positive topline data from our Phase 2a obesity study, in which aleniglipron demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks (p<0.0001, using least-squares means ("LSM") and analyzed based on the primary efficacy estimand using a mixed model for repeated measures) and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120 mg." https://www.sec.gov/Archives/edgar/data/1888886/000155837025001826/gpcr-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001826): "In June 2024, the Company reported positive topline data from the Phase 2a obesity study in which GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks (p<0.0001) and generally favorable safety and tolerability results following repeated, daily dosing up to 120 mg." https://www.sec.gov/Archives/edgar/data/1888886/000155837025001826/gpcr-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015531): "In June 2024, we reported positive topline data from our Phase 2a obesity study, in which GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks (p<0.0001, using least-squares means ("LSM") and analyzed based on the primary efficacy estimand using a mixed model for repeated measures) and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120mg." https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm
- SEC Form 10-Q (accession 0001558370-24-015531): "We further reported topline Phase 2a obesity cohort data, in which GSBR-1290 demonstrated significant reductions in weight at 8 weeks and positive topline data in June 2024, in which GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120mg." https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm
- SEC Form 10-Q (accession 0001558370-24-015531): "We further reported positive topline data from our Phase 2a obesity cohort in June 2024, in which GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120mg." https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm
- SEC Form 10-Q (accession 0001558370-24-015531): "We further reported interim Phase 2a obesity cohort data, in which GSBR-1290 demonstrated significant reductions in weight at 8 weeks and positive topline data in June 2024, in which GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120mg." https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-02-27, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-046149): "Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025" https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/tm2514150d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-046149): ""We continue to make strong progress with the Phase 2b ACCESS and ACCESS II studies for aleniglipron, our once-daily oral small molecule GLP-1 program, which are on track for data readout by the end of the year." https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/tm2514150d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-107740): "ACCESS and ACCESS II Studies on track for topline 36-week data readouts by year-end 2025" https://www.sec.gov/Archives/edgar/data/1888886/000110465925107740/tm2530323d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-018275): "Enrollment in both the ACCESS and ACCESS II studies, totaling over 300 patients, has been completed on schedule and topline 36-week data from both studies are expected by year-end 2025." https://www.sec.gov/Archives/edgar/data/1888886/000110465925018275/tm257591d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-046149): "The Phase 2b ACCESS and ACCESS II studies are fully enrolled and on track for topline 36-week data by year-end 2025." https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/tm2514150d1_ex99-1.htm

### December 8, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2024-11-13, last confirmed 2025-12-08.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-119095): "Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity." https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/tm2532078d2_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-018275): "Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025" https://www.sec.gov/Archives/edgar/data/1888886/000110465925018275/tm257591d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-117691): "Topline data from the ACCESS and ACCESS II studies are expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1888886/000110465924117691/tm2428324d1_ex99-1.htm
- SEC Form 10-Q (accession 0001558370-25-010541): "In February 2025, we completed enrollment in both the ACCESS and ACCESS II studies, and expect to report topline data from both studies in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1888886/000155837025010541/gpcr-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010541): "In February 2025, we completed enrollment in the ACCESS and ACCESS II studies, and we expect to report topline data from both studies in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1888886/000155837025010541/gpcr-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006989): "In February 2025, we completed enrollment in both the ACCESS and ACCESS II studies, and expect to report topline data from both studies in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006989): "In February 2025, we completed enrollment in the ACCESS and ACCESS II studies, and we expect to report topline data from both studies in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001826): "In February 2025, we completed enrollment in the ACCESS and ACCESS II studies, and we expect to report topline data from both studies in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1888886/000155837025001826/gpcr-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015531): "We expect to report topline data from both the ACCESS and ACCESS II studies in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-107829): "In February 2025, we completed enrollment in both the ACCESS and ACCESS II studies, and expect to report topline data from both studies by year-end 2025." https://www.sec.gov/Archives/edgar/data/1888886/000110465925107829/gpcr-20250930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-107829): "In February 2025, we completed enrollment in the ACCESS and ACCESS II studies, and we expect to report topline data from both studies by year-end 2025." https://www.sec.gov/Archives/edgar/data/1888886/000110465925107829/gpcr-20250930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-074712): "Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts" https://www.sec.gov/Archives/edgar/data/1888886/000110465925074712/tm2522431d1_ex99-1.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-12-08, last confirmed 2025-12-10.
- SEC prospectus (424B) (accession 0001104659-25-120013): "Data from ACCESS, ACCESS II, body composition, and the ACCESS OLE studies provide a strong foundation to advance aleniglipron into Phase 3 clinical development and the Company expects to report topline results for these studies in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1888886/000110465925120013/tm2532078-4_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-119370): "Data from ACCESS, ACCESS II, body composition, and the ACCESS OLE studies provide a strong foundation to advance aleniglipron into Phase 3 clinical development and the Company expects to report topline results for these studies in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1888886/000110465925119370/tm2532078-3_424b5.htm

### March 16, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2024-11-13, last confirmed 2026-03-16.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-028023): "Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity." https://www.sec.gov/Archives/edgar/data/1888886/000110465926028023/tm268880d1_ex99-1.htm
- SEC Form 10-Q (accession 0001558370-24-015531): "We expect to report topline data from both the ACCESS and ACCESS II studies in the fourth quarter of 2025 and from an additional Phase 2 study of GSBR-1290 for T2DM, which we expect to initiate by the end of 2024." https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm

### Q3 2026: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-12-08, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-092017): "Topline 72-week aleniglipron ACCESS OLE data on track for Q3 2026;" https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-092057): "We anticipate topline results from the ACCESS OLE trial in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1888886/000110465926092057/gpcr-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-057230): "We anticipate topline results from the ACCESS OLE study in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1888886/000110465926057230/gpcr-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-020562): "Topline data from the study are expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/gpcr-20251231x10k.htm
- SEC prospectus (424B) (accession 0001104659-25-120013): "In the second half of 2026, the Company expects to report topline results from its maintenance switching study evaluating the transition from an approved injectable GLP1-RA injectable to aleniglipron for weight loss" https://www.sec.gov/Archives/edgar/data/1888886/000110465925120013/tm2532078-4_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-119370): "In the second half of 2026, the Company expects to report topline results from its maintenance switching study evaluating the transition from an approved injectable GLP1-RA injectable to aleniglipron for weight loss" https://www.sec.gov/Archives/edgar/data/1888886/000110465925119370/tm2532078-3_424b5.htm

### Aug 2026: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2026-11-09, last confirmed 2026-11-09.
- SEC Form 10-Q (accession 0001104659-26-124503): "In August 2026, we initiated the Phase 3 ACCOMPLISH program, which includes two clinical trials evaluating aleniglipron." https://www.sec.gov/Archives/edgar/data/1888886/000110465926124503/gpcr-20260930x10q.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: obesity or overweight and type 2 diabetes mellitus.
- First seen 2025-12-08, last confirmed 2026-11-09.
- SEC Form 10-Q (accession 0001104659-26-124503): "We anticipate topline results from the body composition trial in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1888886/000110465926124503/gpcr-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-092057): "We anticipate topline results from the body composition trial in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1888886/000110465926092057/gpcr-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-057230): "We anticipate topline results from the body composition study in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1888886/000110465926057230/gpcr-20260331x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124494): "Additional aleniglipron data expected in the fourth quarter of 2026 include topline results from three supplementary clinical trials designed to build on the Phase 2 findings and further characterize aleniglipron's clinical profile:" https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-119095): "In the second half of 2026, the Company expects to report topline results from its maintenance switching study evaluating the transition from an approved injectable GLP1-RA injectable to aleniglipron for weight loss maintenance (SWITCH study), and its Phase 2 randomized placebo controlled study assessing aleniglipron at doses of up to 240mg in patients living with obesity or overweight and type 2 diabetes mellitus (T2DM study)." https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/tm2532078d2_8k.htm

### 2H 2028: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-09-08, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124494): "topline data expected in 2H 2028" https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124494): "Topline data are expected in the second half of 2028." https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-105688): "ALENIGLIPRON On track to complete enrollment by 1H 2027 and topline data in 2H 2028" https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-105688): "Phase 3 clinical trials for aleniglipron enrollment ongoing; topline data expected in 2H 2028" https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/aleniglipron.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Aleniglipron PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/aleniglipron

```bibtex
@misc{secapidev_pdufa_aleniglipron_20261116,
  title        = {Aleniglipron PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/aleniglipron}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_aleniglipron_20261116","title":"Aleniglipron PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/aleniglipron","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
